ZYMEWORKS INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)

ITEM 7.01 REGULATION FD DISCLOSURE

On September 12, 2022, Zymeworks Inc. ("Zymeworks") issued a press release announcing that it presented preliminary results from Zymeworks' Phase 1 clinical trial evaluating zanidatamab zovodotin (ZW49) for the treatment of HER2-positive tumors.

On September 12, 2022, Zymeworks filed this press release with the Canadian securities regulatory authorities on the System for Electronic Document Analysis and Retrieval at www.sedar.com.

A copy of this press release is attached as Exhibit 99.1 hereto.

The information under this Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto are being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act"), or otherwise subject to the liability of that section, nor shall such information be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, regardless of the general incorporation language of such filing, except as shall be expressly set forth by specific reference in such filing.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

(d) Exhibits

Exhibit
  No.     Description

99.1        Press Release dated September 12, 2022.

104       Cover Page Interactive Data File (embedded as Inline XBRL document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses